Bempikibart Shows Durable Off-Drug Response in Phase 2a Alopecia Areata Trial
QTTB has more than doubled off its 52-week low of $1.83.
Summary
Full SIGNAL-AA Part B data showed durable off-drug responses and a clean safety profile, supporting advancement to a registration-directed program in H1 2027.
Key Events · Product Development and Regulatory · QTTB
-
Durable Off-Drug Response Demonstrated
At 16 weeks off-drug, 44% of patients achieved SALT-20, 61% achieved SALT-30, and 50% achieved SALT-50. Among 12 patients with hair growth at Week 36, 100% maintained response and 42% deepened response.
-
Clean Safety Profile Confirmed
No serious adverse events or Grade 3+ treatment-related events were reported. The most common AE was injection site reaction (36.3% of patients, 4% of all administrations), all mild and self-resolving.
-
Registration-Directed Program Planned
The company plans to advance bempikibart into a registration-directed program for severe/very severe AA in H1 2027, subject to regulatory discussions in H2 2026. OLE data are expected in H2 2027.
-
Biomarker and PK Data Support Mechanism
The loading dose achieved steady state ~10 weeks earlier than Part A. Reductions in IFNγ, IL-17, IL-6, CXCL10, TARC, IgE, and eosinophils were observed. ADA was negligible with no impact on PK.
Analysis · QTTB · Life Sciences
Full 36-week and 16-week off-drug data from the SIGNAL-AA Part B trial were presented at EADV 2026, adding materially to the July topline. The key new finding is durability: 100% of patients who had hair growth at Week 36 maintained their response through 16 weeks off-drug, and 42% deepened their response. This supports a less frequent, chronic maintenance dosing regimen — a potential differentiator versus JAK inhibitors that require continuous dosing. The safety profile remains clean with no SAEs or Grade 3+ treatment-related events. A registration-directed program is now planned for H1 2027, subject to regulatory discussions in H2 2026. For a $284M market cap biotech with $106M in cash, this data de-risks the path to Phase 3 and strengthens the case for bempikibart as a first-line AA treatment.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QTTB was trading at $10.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.7M. The 52-week trading range was $1.83 to $23.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.